Sponsored Content

Articles by Sponsored Content

POLIVY + BR: A Therapeutic Option Granted Accelerated Approval for R/R 3/L+DLBCL, NOS

BySponsored Content

February 2nd 2020

The Proposed Mechanism of Action of POLIVY for R/R DLBCL, NOS

BySponsored Content

February 1st 2020

Vincent Herrin, MD - University of Mississippi Medical Center Jackson, Mississippi

Latest Updated Articles

POLIVY + BR: A Therapeutic Option Granted Accelerated Approval for R/R 3/L+DLBCL, NOS
February 2nd 2020
The Proposed Mechanism of Action of POLIVY for R/R DLBCL, NOS
February 1st 2020

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

NCCN Survey Finds Persistent Cancer Drug Shortages Across US Centers

Risk-Adapted Quadruplet Therapy Sustains 5-Year Survival Benefit in High-Risk Myeloma

FDA Grants Final Approval to Cabozantinib Capsule Formulation

Subcostal Robotic Surgery Cuts Thoracic Pain

Rewriting the Playbook: How Biomarker-Driven Therapy Is Transforming Metastatic Prostate Cancer Care